诺和诺德全球高级副总裁兼大中国区总裁蔡琰:立足司美原研优势 挑战中寻找更大机遇

21世纪经济报道
Apr 15

2026年3月,诺和诺德明星产品司美格鲁肽核心化合物在中国的专利到期。随着这一时间节点的到来,国内多款生物类似药的申报已进入冲刺阶段,市场对这家丹麦制药巨头在华策略的关注度持续升温。  “专利到期不是终点。”履新刚满一个月的诺和诺德全球高级副总裁兼大中国区总裁蔡琰博士,在其首场媒体交流活动中给出了明确回应。这位在诺和诺德工作了23年、几乎参与了公司近二十年来所有新药研发的老将,刚从国外回到中国,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10